RxDoctor Payments Data

Stephen Fox, MD

Ophthalmology · Spencer, IANPI 1548221328

Payments from drug & device makers

What this record shows

The money is spread across several categories — ownership interests (50.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by US Retina LLC at 50.4% of the total. Reporting peaked in 2024 at $1,465 and has fallen 80.8% since, to $281 in 2025.

$4,770in general payments, 2019–2025

Across 87 payments — averaging $54.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$2K
  • Alcon$2K
  • Bausch & Lomb Americas Inc.$198
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$195
  • Sight Sciences, Inc.$116
  • Regeneron Healthcare Solutions, Inc.$62
  • plus $64 from 3 others

What the payments were for

  • Travel & lodging$1,04622%
  • Food & beverage$1,32128%
  • Ownership interest$2,40350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,770 in reported general payments places this provider in the 80th percentile of 172 ophthalmology providers in Iowa.

See all ophthalmology providers in Iowa

Medicare billing

Part B allowed, 2024
$1,003,197
Medicare patients
1,615
Services billed
8,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine53$36,796
RocklatanNetarsudil Mesylat/Latanoprost74$24,997
LumiganBimatoprost72$20,469
Ketorolac Tromethamine1,009$18,633
RhopressaNetarsudil Mesylate41$12,940
SimbrinzaBrinzolamide/Brimonidine Tart45$8,888
Alphagan PBrimonidine Tartrate26$5,306
Latanoprost636$4,423
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat216$3,683
Prednisolone Acetate52$2,438
ValacyclovirValacyclovir Hcl37$1,773
Timolol Maleate156$1,239
Dorzolamide-TimololDorzolamide/Timolol/Pf12$1,197
Brimonidine Tartrate132$1,012
MoxifloxacinMoxifloxacin Hcl17$854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$1,732$8,88845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 172 ophthalmology providers in Iowa.

Other ophthalmology in Spencer

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →